From Wikipedia, the free encyclopedia
(Redirected from )
This article may require
to meet Wikipedia's . The specific problem is: consistent capitalization. Please help
if you can. (June 2013)
In , human chorionic gonadotropin (hCG) is a
produced by the , a portion of the
following implantation. The presence of hCG is detected in . Some cancerous tumors
therefore, elevated levels measured when the patient is not pregnant can lead to a cancer diagnosis. However, it is not known whether this production is a contributing cause or an effect of . The pituitary analog of hCG, known as
(LH), is produced in the
of males and females of all ages. As of December 6, 2011, the United States FDA has prohibited the sale of "homeopathic" and over-the-counter hCG diet products and declared them fraudulent and illegal.
Human chorionic gonadotropin is a
composed of 237
It is , with an α (alpha)
identical to that of
(TSH), and β (beta) subunit that is unique to hCG.
is 92 amino acids long.
The β-subunit of hCG gonadotropin (beta-hCG) contains 145 amino acids, encoded by six highly homologous
that are arranged in tandem and inverted pairs on 13.3 - CGB (, , , , , )
The two subunits create a small
core surrounded by a high surface area-to-volume ratio: 2.8 times that of a sphere. The vast majority of the outer amino acids are .
Human chorionic gonadotropin interacts with the
of the ovary and promotes the maintenance of the
during the beginning of . This allows the corpus luteum to
the hormone
during the first trimester. Progesterone enriches the
with a thick
so that it can sustain the growing . Due to its highly negative charge, hCG may repel the immune cells of the mother, protecting the fetus during the first trimester. It has also been hypothesized that hCG may be a placental link for the development of local maternal . For example, hCG-treated endometrial cells induce an increase in T cell
(dissolution of ). These results suggest that hCG may be a link in the development of peritrophoblastic immune tolerance, and may facilitate the
invasion, which is known to expedite fetal development in the endometrium. It has also been suggested that hCG levels are linked to the severity of
in pregnant women.
Because of its similarity to , hCG can also be used clinically to induce
as well as
production in the testes. As the most abundant biological source is women who are presently pregnant, some organizations collect urine from pregnant women to extract hCG for use in .
Human chorionic gonadotropin also plays a role in /proliferation and may activate .
Like other , it can be extracted from the urine of pregnant women or extracted from cultures of genetically modified microbes with .
and , it is extracted from the urine of a pregnant mare. In , it is protein expressed by microbes with .
Naturally, it is produced in the placenta by the .
Total hCG, C-terminal peptide total hCG, intact hCG, free β-subunit hCG, β-core fragment hCG, hyperglycosylated hCG, nicked hCG, alpha hCG, pituitary hCG.
tests measure hCG. These can be . hCG-positive indicates an implanted
and . These can be done to diagnose and monitor
Concentrations are commonly reported in thousandth international units per milliliter (mIU/ml). The international unit of hCG was originally established in 1938 and has been redefined in 1964 and in 1980. At the present time, 1 international unit is equal to approximately 2.35×10-12 moles, or about 6×10-8 grams.
Most tests employ a monoclonal antibody, which is specific to the β-subunit of hCG (β-hCG). This procedure is employed to ensure that tests do not make
by confusing hCG with LH and FSH. (The latter two are always present at varying levels in the body, whereas the presence of hCG almost always indicates pregnancy.)
Many hCG immunoassays are based on the , which uses antibodies to hCG labeled with an enzyme or a conventional or luminescent dye. Pregnancy urine dipstick tests are based on the
technique.
may be a chromatographic
or any of several other test formats, home-, physician's office-, or laboratory-based. Published detection thresholds range from 20 to 100 mIU/ml, depending on the brand of test. Early in pregnancy, more accurate results may be obtained by using the first urine of the morning (when hCG levels are highest). When the urine is dilute ( less than 1.015), the hCG concentration may not be representative of the blood concentration, and the test may be falsely negative.
test, using 2-4 mL of venous blood, is typically a chemiluminescent or fluorimetric immunoassay that can detect βhCG levels as low as 5 mIU/ml and allows quantification of the βhCG concentration.
The following is a list of serum hCG levels. (LMP is the
dated from the first day of your last period.) The levels grow exponentially after conception and implantation.
weeks since LMP
18 – 7,340
1,080 – 56,500
7,650 – 229,000
25,700 – 288,000
13,300 – 254,000
4,060 – 165,400
3,640 – 117,000
Non-pregnant females
Postmenopausal females
The ability to quantitate the βhCG level is useful in the monitoring
and , follow-up care after , and in diagnosis of and follow-up care after treatment of . The lack of a visible fetus on vaginal
after the βhCG levels have reached 1500 mIU/ml is strongly indicative of an ectopic pregnancy. Still, even an hCG over 2000 IU/l does not necessarily exclude the presence of a viable intrauterine pregnancy in such cases.
As pregnancy tests, quantitative blood tests and the most sensitive urine tests usually detect hCG between 6 and 12 days after ovulation. However, it must be taken into account that total hCG levels may vary in a very wide range within the first 4 weeks of gestation, leading to false results during this period. A rise of 35% over 48 hours is proposed as the minimal rise consistent with a viable intrauterine pregnancy.
Gestational trophoblastic disease like
("molar pregnancy") or choriocarcinoma may produce high levels of βhCG (due to the presence of syncytialtrophoblasts- part of the villi that make up the placenta) despite the absence of an embryo. This, as well as several other conditions, can lead to elevated hCG readings in the absence of pregnancy.
hCG levels are also a component of the , a screening test for certain fetal chromosomal abnormalities/birth defects.
A study of 32 normal pregnancies came to the result a
of 1-3 mm was detected at a mean hCG level of 1150 UI/l (range 800-1500), a
was detected at a mean level of 6000 UI/l (range ) and
was visible at a mean hCG level of 10,000 UI/l (range ).
Human chorionic gonadotropin can be used as a , as its β subunit is secreted by some
including , , ,
formation,
with elements of , and . For this reason a positive result in males can be a test for . The normal range for men is between 0-5 mIU/mL. Combined with , β-HCG is an excellent tumor marker for the monitoring of .[]
Human chorionic gonadotropin is extensively used
in lieu of . In the presence of one or more mature ovarian follicles, ovulation can be triggered by the administration of HCG. As
will happen between 38 and 40 hours after a single HCG injection, procedures can be scheduled to take advantage of this time sequence, such as
or sexual intercourse. Also, patients that undergo , in general, receive HCG to trigger the ovulation process, but have an
performed at about 34 to 36 hours after injection by, a few hours before the eggs actually would be released from the ovary.
As HCG supports the , administration of HCG is used in certain circumstances to enhance the production of .
In the male, HCG injections are used to stimulate the
to synthesize . The intratesticular testosterone is necessary for
from the . Typical uses for HCG in men include
and fertility treatment.
During first few months of pregnancy, the transmission of
from woman to fetus is extremely rare. It has been suggested that this is due to the high concentration of HCG, and that the beta-subunit of this protein is active against HIV-1.
In the case of female patients who want to be treated with HCG Pregnyl: a) Since infertile female patients who undergo medically assisted reproduction (especially those who need ), are known to often be suffering from tubal abnormalities, after a treatment with this drug they might experience many more . This is why early ultrasound confirmation at the beginning of a pregnancy (to see whether the pregnancy is intrauterine or not) is crucial. - Pregnancies that have occurred after a treatment with this medicine are submitted to a higher risk of multiplets. - Female patients who have thrombosis, severe obesity or thrombophilia should not be prescribed this medicine as they have a higher risk of arterial or venous thromboembolic events after or during a treatment with HCG Pregnyl. b)Female patients who have been treated with this medicine are usually more prone to pregnancy losses.
In the case of male patients: A prolonged treatment with HCG Pregnyl is known to regularly lead to increased production of androgen. Therefore: Patients who are suffering from overt or latent cardiac failure, hypertension, renal dysfunction, migraines or epilepsy might not be allowed to start using this medicine or may require a lower dose of HCG Pregnyl. Also this medicine should be used with extreme caution in the treatment of prepubescent teenagers in order to reduce the risk of precocious sexual development or premature epiphyseal closure. This type of patients' skeletal maturation should be closely and regularly monitored.
Both male and female patients who have the following medical conditions must not start a treatment with HCG Pregnyl: (1) Hypersensitivity to this medicine or to any of its main ingredients. (2) Known or possible androgen-dependent tumors for example male breast carcinoma or prostatic carcinoma.
In the world of performance-enhancing drugs, HCG is increasingly used in combination with various
(AAS) cycles. As a result, HCG is included in some sports' illegal drug lists.
When exogenous AAS are put into the male body, natural negative-feedback loops cause the body to shut down its own production of
via shutdown of the hypothalamic-pituitary-gonadal axis (). This causes testicular atrophy, among other things. HCG is commonly used during and after steroid cycles to maintain and restore testicular size as well as normal testosterone production.
High levels of AASs, that mimic the body's natural testosterone, trigger the
to shut down its production of
(GnRH) from the hypothalamus. Without GnRH, the
stops releasing
(LH). LH normally travels from the pituitary via the blood stream to the testes, where it triggers the production and release of testosterone. Without LH, the testes shut down their production of testosterone. In males, HCG helps restore and maintain testosterone production in the testes by mimicking LH and triggering the production and release of testosterone.
If HCG is used for too long and in too high a dose, the resulting rise in natural testosterone would eventually inhibit its own production via negative feedback on the hypothalamus and pituitary gland.[]
Professional athletes who have tested positive for HCG have been temporarily banned from their sport, including a 50-game ban from
in 2009 and a 4-game ban from the
for a positive urine test for HCG.
was fined $19,800 and suspended 9 months for being tested positive after his bout at .
"HCG Diet"[]
British endocrinologist
proposed HCG as an adjunct to an ultra-low-calorie weight-loss diet (less than 500 calories). Simeons, while studying pregnant women in India on a calorie-deficient diet, and "fat boys" with pituitary problems () treated with low-dose HCG, observed that both lost fat rather than lean (muscle) tissue. He reasoned that HCG must be programming the
to do this in the former cases in order to protect the developing fetus by promoting mobilization and consumption of abnormal, excessive
deposits. Simeons in 1954 published a book entitled Pounds and Inches, designed to combat obesity. Simeons, practicing at Salvator Mundi International Hospital in Rome, Italy, recommended low-dose daily HCG injections (125 IU) in combination with a customized ultra-low-calorie (500 cal/day, high-protein, low-carbohydrate/fat) diet, which was supposed to result in a loss of adipose tissue without loss of lean tissue.
Simeons' results were not reproduced by other researchers and in 1976 in response to complaints the FDA required Simeons and others to include the following disclaimer on all advertisements:
These weight reduction treatments include the injection of HCG, a drug which has not been approved by the Food and Drug Administration as safe and effective in the treatment of obesity or weight control. There is no substantial evidence that HCG increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or "normal" distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restrictive diets.
— 1976 FDA-mandated disclaimer for HCG diet advertisements
There was a resurgence of interest in the "HCG diet" following promotion by
who was later banned from making HCG diet weight-loss claims by the U.S. .
Review studies refuting the HCG diet have been published in the
and the American Journal of Clinical Nutrition, both concluding that HCG is neither safe nor effective as a weight-loss aid.
A meta analysis found that studies supporting HCG for weight loss were of poor methodological quality and concluded that "there is no scientific evidence that HCG is effective in the
it does not bring about weight-loss or fat-redistribution, nor does it reduce hunger or induce a feeling of well-being".
There is no scientific evidence that HCG is effective in the treatment of obesity. The meta-analysis found insufficient evidence supporting the claims that HCG is effective in altering fat-distribution, hunger reduction or in inducing a feeling of well-being. The authors stated “…the use of HCG should be regarded as an inappropriate therapy for weight reduction…” In the authors opinion, “Pharmacists and physicians should be alert on the use of HCG for Simeons therapy. The results of this meta-analysis support a firm standpoint against this improper indication. Restraints on physicians practicing this therapy can be based on our findings.”
— American Society of Bariatric Physicians' commentary on Lijesen et. al (1995)
According to the American Society of Bariatric Physicians, no new clinical trials have been published since the definitive 1995 meta-analysis.
The scientific consensus is that any weight loss reported by individuals on an "HCG diet" may be attributed entirely to the fact that such diets prescribe calorie intake of between 500 and 1,000 calories per day, substantially below recommended levels for an adult, to the point that this may risk health effects associated with malnutrition.
Controversy about, and shortages of, injected HCG for weight loss have led to substantial Internet promotion of " HCG" for weight control. The ingredients in these products are often obscure, but if prepared from true HCG via homeopathic dilution, they contain either no HCG at all or only trace amounts. Moreover, it is highly unlikely that oral HCG is bioavailable due to the fact that digestive protease enzymes and hepatic metabolism renders peptide-based molecules (such as insulin and human growth hormone) biologically inert. HCG can likely only enter the bloodstream through injection.
The United States
has stated that over-the-counter products containing HCG are fraudulent and ineffective for weight loss. They are also not protected as homeopathic drugs and have been deemed illegal substances. HCG itself is classified as a prescription drug in the United States and it has not been approved for over-the-counter sales by the FDA as a weight loss product or for any other purposes, and therefore neither HCG in its pure form nor any preparations containing HCG may be sold legally in the country except by prescription. In December 2011, FDA and FTC started to take actions to pull unapproved HCG products from the market. In the aftermath, some suppliers started to switch to "hormone-free" versions of their weight loss products, where the hormone is replaced with an unproven mixture of free amino acids or where
is used to transfer the "energy" to the final product.
- a screening test in pregnancy
- Kevin Trudeau's book
Cole LA (2009). . Reprod. Biol. Endocrinol. 7: 8. :.  .  .
Gregory JJ, Finlay JL (April 1999). "Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers". Drugs 57 (4): 463–7. :.  .
Hoermann R, Spoettl G, Moncayo R, Mann K (July 1990). "Evidence for the presence of human chorionic gonadotropin (hCG) and free beta-subunit of hCG in the human pituitary". J. Clin. Endocrinol. Metab. 71 (1): 179–86. :.  .
Gever, John (December 6, 2011). .
. FDA. December 6, 2011.
(Press release). FDA. December 6, .
; Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, Morgan FJ, Isaacs NW (June 1994). "Crystal structure of human chorionic gonadotropin". Nature 369 (6480): 455–61. :.  .
. UniProt accession number P01215. UniProt Consortium. P]
. UniProt accession number P01233. UniProt Consortium. P]
Kayisli U, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A (2003). "Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system". J. Immunol. 171 (5): 2305–13. :.  .
Askling J, Erlandsson G, Kaijser M, Akre O, Ekbom A (December 1999). "Sickness in pregnancy and sex of child". Lancet 354 (9195): 2053. :.  .
- a Dutch organization that collects urine from pregnant women to extract hCG.[]
(pdf). Prescribing Information. Merck & Co., Inc.
Michels KB, Xue F, Colditz GA, Willett WC (April 2007). "Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study". Arch. Intern. Med. 167 (8): 814–20. :.  .
Canfield RE, Ross GT (1976). . Bulletin of the World Health Organization 54 (4): 463–472.  .  .
Richard A. McPherson, Matthew R. Pincus, (2006). Henry's Clinical Diagnosis and Management by Laboratory Methods (21st ed.). Philadelphia: Saunders.  .[]
Waddell, Rebecca Smith (2006). . Home Pregnancy Test hCG Levels and FAQ.
Tualndi, Togas. . UpToDate 2013.
Kirk, E.; Bottomley, C.; Bourne, T. (2013). "Diagnosing ectopic pregnancy and current concepts in the management of pregnancy of unknown location". Human Reproduction Update 20 (2): 250–261. :.  .  .
Wilcox AJ, Baird DD, Weinberg CR (1999). "Time of implantation of the conceptus and loss of pregnancy". New England Journal of Medicine 340 (23): . :.  .
Butler SA, Khanlian SA, Cole LA (2001). "Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices". Clinical Chemistry 47 (12): .  .
Giacomello F, Magliocchetti P, Loyola G, Giovarruscio M (1993). "[Serum beta hCG levels and transvaginal echography in the early phases of pregnancy]". Minerva Ginecol (in Italian) 45 (7-8): 333–7.  .
. American Cancer Society 2014.
at Medscape. By Peter Kovacs. Posted: 04/23/2004
; Ovulation Induction. Retrieved Mars 7, 2010[]
Lee-Huang S, Huang PL, Sun Y, Huang PL, Kung HF, Blithe DL, Chen HC (March 1999). . Proc. Natl. Acad. Sci. U.S.A. 96 (6): 2678–81. :.  .  .
Williams, Lance (May 8, 2009). . San Francisco Chronicle.
van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH (April 2003). "Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study". Int J Sports Med 24 (3): 195–6. :.  .
Schmidt, Michael S. (May 8, 2009). . The New York Times.
Holland, Jesse S. (April 24, 2014). . <.
Simeons ATW (2010). Pounds & Inches: A New Approach To Obesity. Popular Publishing. &#160;.
In the Matter of Simeon Management Corp. (Fed. Trade Comm'n, 1976) 87 F.T.C. 1184; affirmed by Simeon Management Corp. v. FTC (9th Cir.
F.2d 1137, 49 ALR-Fed 1.
; FTC v. Trudeau (7th Cir.,
F.3d 754 remanded (N.D.Ill.,
F.Supp.2d 711, affirmed (7th Cir.
F.3d 947, certiorari denied (Oct. 9, 2012) _U.S._, 133 S.Ct. 426, 184 L.Ed.2d 257; and a ten-year prison sentence for violating a court order, U.S. v. Trudeau (N.D.Ill., Jan. 29,
u.s.dist. LEXIS 1 WL 321373. And the article, The Curious Case of Kevin Trudeau, King Catch Me If You Can by Catherine Bryant Bell, Mississippi Law Journal, vol. 79 page 1043 (summer 2010), .
Stein MR, Julis RE, Peck CC, Hinshaw W, Sawicki JE, Deller JJ (September 1976). . Am. J. Clin. Nutr. 29 (9): 940–8. &#160;.
Barrett S. . Diet Scam Watch. dietscam.org.
Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G (September 1995). . Br J Clin Pharmacol 40 (3): 237–43. :. &#160;. &#160;.
, position statement on HCG diet
. Bulletin. American Society of Health-System Pharmacists. .
Phillips J (). . Epoch Times.
Hellmich N (). . USA Today.
. San Francisco Chronicle. March 9, 2012.
at the US National Library of Medicine
1hrp: CRYSTAL STRUCTURE OF HUMAN CHORIONIC GONADOTROPIN&#160;
1qfw: TERNARY COMPLEX OF HUMAN CHORIONIC GONADOTROPIN WITH FV ANTI ALPHA SUBUNIT AND FV ANTI BETA SUBUNIT&#160;
: Hidden categories: